The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
about
Quetiapine versus other atypical antipsychotics for schizophreniaAntipsychotic drug treatment for elderly people with late-onset schizophreniaZiprasidone versus other atypical antipsychotics for schizophreniaSchizophrenia: a multisystem disease?Detection of metabolic syndrome in schizophrenia and implications for antipsychotic therapy : is there a role for folate?Postmortem brain: an underutilized substrate for studying severe mental illnessMouse pharmacological models of cognitive disruption relevant to schizophrenia.Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosisCardiovascular risk factors and metabolic syndrome in people with established psychotic illnesses: baseline data from the IMPaCT randomized controlled trial.Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care.Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general populationEndothelial nitric oxide synthetase genetic variants, metabolic syndrome and endothelial function in schizophrenia.Testing covariates of Type 2 diabetes-cognition associations in older adults: moderating or mediating effects?Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review.Ziprasidone hydrocloride: what role in the management of schizophrenia?Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.Effects of switching from olanzapine to aripiprazole on the metabolic profiles of patients with schizophrenia and metabolic syndrome: a double-blind, randomized, open-label studyComparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia.Quality of life in schizophrenic patients.Metabolic abnormalities among people diagnosed with schizophrenia: a literature review and implications for mental health nurses.Endothelial function, folate pharmacogenomics, and neurocognition in psychotic disordersPredictors of quality of life among individuals with schizophrenia.Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs.Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.Perceived needs and health-related quality of life in people with schizophrenia and metabolic syndrome: a "real-world" study.Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study.Metabolic adverse events in patients with mental illness treated with antipsychotics: a primary care perspective.Evidence review and clinical guidance for the use of ziprasidone in Canada.Metabolic syndrome in patients with severe mental illness undergoing psychiatric rehabilitation receiving high dose antipsychotic medication.A case series: evaluation of the metabolic safety of aripiprazoleSexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder.Prevalence of metabolic syndrome and its association with depression in patients with schizophreniaLifestyle related factors & impact of metabolic syndrome on quality of life, level of functioning & self-esteem in patients with bipolar disorder & schizophrenia.The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients.Metabolic syndrome in people with schizophrenia: a review.
P2860
Q24202427-8099004B-88EB-47E0-B42F-E6B15EC9D00AQ24203649-7E90FD23-5A9A-436A-A5B1-B0C5591AA20AQ24240260-B6531A21-9E4C-4FAA-B1F2-33E0458C0235Q24633845-B8271E7B-7E4D-4BF9-A45A-BBAEC8684366Q26864342-57AC4D56-7EE4-4A4F-8C34-582443B47C0BQ30422050-56369D69-FC7B-4CAD-A9AE-7E3FB4EFBE4CQ30457807-7FC314A8-74EC-4883-AAD7-A2A18493D342Q30489404-F7736613-F6EC-4DE9-B5BC-111F4D863158Q30723937-2BC9102E-3996-4505-86F4-986E61EF8C1AQ30949176-C483AF29-AA4C-47BB-92D0-4C582527DBA9Q33257886-863D676F-8A15-4C41-8D1D-5FCADE1531B8Q33442059-2785719A-2802-4B07-8DA0-6652FDF75B32Q33622056-5889BB72-EBF9-4E54-904E-D2FC89B7AD8EQ33688651-B5AF9777-CFBD-46F8-8FC9-9FF1D50B2A46Q34102777-3BCF1CC3-6EDB-4AF8-AA3D-E63B6E917E05Q34181934-E81DC278-83BF-4445-8229-F873B165DF48Q34357931-42F6E73B-0882-4F17-9D1B-7F60AAF289C5Q34631699-E1380A4F-DCF8-44BB-8AD3-C2D98179A671Q35115972-EE66E8B5-E979-4413-AD36-FE12D0536F8DQ35191252-CFEEB3ED-402C-4C1A-90C3-BAB7EA940E69Q35230391-502E1481-3A2E-4E21-B694-3176A41948FEQ35236921-C28CA9B2-0ECD-4BFD-9C1A-5DAE6EB9C150Q35530406-BAEBCCA8-0718-49E0-9321-B1D94747BBE1Q35537186-8907B673-BAB9-429C-92C1-E23F89DD5BF1Q35683796-71C012BC-AC1E-4910-8CE8-B21F51D185A9Q36063735-DD5F9169-C15C-46E4-853C-FC4C12259BD9Q36178681-C39619CC-8C19-4E63-8A2A-B137E929CB2FQ36198276-7B66D82F-A34D-4358-854B-ED4CED88DA76Q36200184-5A3AEE9D-FD24-46C9-A57B-76C51F883271Q36439996-78CBF364-6EFC-45BB-A5A0-E2BC9ED8A06AQ36474147-23FA24F9-13E1-4CD1-BB7F-2D8380BFD3ECQ36588607-170055B2-7C1C-42BB-ADDA-6BB14320289DQ36613083-5EFA78F9-3F42-40D2-A6DA-1F637FE0EE9AQ36853249-DEC322FE-4A49-4797-B4DA-6646238B06E3Q36882931-F159B8C0-AC03-4C9E-84E3-9CACEE421163Q37007481-080E071E-BCA0-43B9-9812-6673B2B864A0Q37055414-95DD84F1-5F74-490E-BB96-C9DE964DEA7AQ37079080-172234F2-59C7-454D-BB0A-BEBD52A73927Q37102229-1DE41CDC-1501-4A4D-A45C-513D9EE5ED6FQ37129646-40BDB0AC-C6FB-4F50-A173-8964DBD129A9
P2860
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndrome.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
The Clinical Antipsychotic Tri ...... ithout the metabolic syndrome.
@en
The Clinical Antipsychotic Trials Of Intervention Effectiveness
@nl
type
label
The Clinical Antipsychotic Tri ...... ithout the metabolic syndrome.
@en
The Clinical Antipsychotic Trials Of Intervention Effectiveness
@nl
prefLabel
The Clinical Antipsychotic Tri ...... ithout the metabolic syndrome.
@en
The Clinical Antipsychotic Trials Of Intervention Effectiveness
@nl
P2093
P50
P1476
The Clinical Antipsychotic Tri ...... without the metabolic syndrome
@en
P2093
Henry A Nasrallah
Jayendra K Patel
Jonathan M Meyer
Joseph P McEvoy
Miranda Chakos
Richard S E Keefe
Sonia M Davis
P356
10.1016/J.SCHRES.2005.07.015
P407
P577
2005-08-24T00:00:00Z